Researchers at the University of Chicago found that after a long stay in the Intensive Care Unit (ICU) only a handful of pathogenic microbe species remain behind in patients’ intestines. The team tested these remaining pathogens and discovered that some can become deadly when provoked by conditions that mimic the body’s stress response to illness. “They’ve got a lot of bad guys in there, but the presence of bad guys alone doesn’t tell you who’s going to live or die,” says John Alverdy, a gastrointestinal surgeon and one of two senior authors on the study. “It’s not only which microbes are there, but how they behave when provoked by the harsh and hostile conditions of critical illness.” By John Alverdy et al, published in mBio®, journal of the American Society for Microbiology.
In 2013, a study, Immunomodulatory Effects of ResistAid™: A Randomized, Double-Blind, Placebo-Controlled, Multidose Study, evaluated the ability of a proprietary arabinogalactan extract from the larch tree (ResistAid™, Lonza Ltd., Basel, Switzerland) to change the immune response in healthy adults to a standardized antigenic challenge of tetanus and influenza vaccines in a dose-dependent manner compared to placebo. As it is flu season, Today’s Practitioner is revisiting the study and the subject with an interview with Bryan Rodriguez, Global Products Manager, of Lonza, makers of Resist Aid. Download the full study at the end of this article.